Projects per year
Abstract
BackgroundReal-world data is lacking on survival in advanced gastro-oesophageal (aGO) cancer patients treated with best supportive care (BSC) only. This knowledge is vital to personalise cancer treatment and obtain truly informed consent. This study aimed to define and compare survival in aGO cancer patients treated with and without palliative chemotherapy (CTx), and to explore the factors that impact prognosis.
MethodsPatients in NHS Tayside, Scotland, diagnosed with aGO adenocarcinoma (defined as non-resectable) between 01/01/2016-31/12/2017 were identified retrospectively. Clinical data was obtained from electronic records. For both groups, survival was defined as date of diagnosis to date of death. Patients in the BSC group either chose not to have CTx or were deemed not suitable. Kaplan-Meier analysis for survival was performed to determine median overall survival (mOS) and Cox Regression analysis used to determine contributing factors. Local ethical approval was obtained.
Results116 eligible patients were identified. There was a significant difference in mOS between patients in the BSC and CTx groups (93 days(d) vs 274 days, p<0.001). This was maintained when those deemed not fit for CTx were removed. One-year survival was 18.7% v 34.1% (p=0.063). Cox regression analysis in the BSC group identified stage (p<0.001) and performance status (PS) (p=0.021) as having independent predictive value for survival. Age was not related to outcome. Those with palliative stents, n= 31, had a mOS 137d v 56d for those who did not, n=44 (p=0.219).
MethodsPatients in NHS Tayside, Scotland, diagnosed with aGO adenocarcinoma (defined as non-resectable) between 01/01/2016-31/12/2017 were identified retrospectively. Clinical data was obtained from electronic records. For both groups, survival was defined as date of diagnosis to date of death. Patients in the BSC group either chose not to have CTx or were deemed not suitable. Kaplan-Meier analysis for survival was performed to determine median overall survival (mOS) and Cox Regression analysis used to determine contributing factors. Local ethical approval was obtained.
Results116 eligible patients were identified. There was a significant difference in mOS between patients in the BSC and CTx groups (93 days(d) vs 274 days, p<0.001). This was maintained when those deemed not fit for CTx were removed. One-year survival was 18.7% v 34.1% (p=0.063). Cox regression analysis in the BSC group identified stage (p<0.001) and performance status (PS) (p=0.021) as having independent predictive value for survival. Age was not related to outcome. Those with palliative stents, n= 31, had a mOS 137d v 56d for those who did not, n=44 (p=0.219).
| Original language | English |
|---|---|
| Article number | S914 |
| Journal | Annals of Oncology |
| Volume | 31 |
| Issue number | Supplement 4 |
| DOIs | |
| Publication status | Published - 1 Sept 2020 |
Access to Document
Fingerprint
Dive into the research topics of 'Real-world survival in advanced gastro-oesophagealadenocarcinoma with best supportive care'. Together they form a unique fingerprint.Projects
- 1 Finished
-
Identifying and Validating Predictive Biomarkers in Advanced Oesophagael Adenocarcinoma - A Springboard to REAListic Medicine (BE-REAL)
Baxter, M. (Investigator)
1/10/20 → 29/02/24
Project: Research